Joseph P. Hagan Purchases 50,000 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) CEO Joseph P. Hagan purchased 50,000 shares of the company's stock in a transaction that occurred on Thursday, January 30th. The stock was acquired at an average cost of $1.09 per share, with a total value of $54,500.00. Following the transaction, the chief executive officer now directly owns 260,808 shares of the company's stock, valued at approximately $284,280.72. This represents a 23.72 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Regulus Therapeutics Stock Performance

Regulus Therapeutics stock traded up $0.11 during trading hours on Tuesday, hitting $1.34. 3,802,677 shares of the stock were exchanged, compared to its average volume of 774,939. The stock has a market capitalization of $87.77 million, a P/E ratio of -1.25 and a beta of 1.58. The business's 50-day moving average is $1.45 and its two-hundred day moving average is $1.53. Regulus Therapeutics Inc. has a 12 month low of $0.83 and a 12 month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). On average, equities analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of Regulus Therapeutics

Several large investors have recently made changes to their positions in RGLS. Renaissance Technologies LLC lifted its position in Regulus Therapeutics by 56.4% during the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company's stock worth $211,000 after buying an additional 42,600 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Regulus Therapeutics in the third quarter worth about $33,000. Creative Planning acquired a new position in shares of Regulus Therapeutics during the third quarter worth approximately $26,000. Tyche Wealth Partners LLC grew its stake in shares of Regulus Therapeutics by 920.6% during the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company's stock valued at $167,000 after purchasing an additional 95,694 shares during the last quarter. Finally, Victory Capital Management Inc. increased its holdings in shares of Regulus Therapeutics by 10.4% in the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company's stock valued at $626,000 after purchasing an additional 37,480 shares in the last quarter. Institutional investors own 92.38% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Regulus Therapeutics in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Regulus Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.